Viewed as a 'dangerous' high-risk, high-reward play. The investment thesis is based on speculation that it is a likely M&A target with a potential buyout price of $150 or $200 per share.

The speaker is 'over the moon about' this stock, making it a high-conviction bullish pick.

The speaker is making a highly speculative bet by buying out-of-the-money call options based on rumors of a potential takeover by 'big pharma', hoping for a massive gain if an acquisition occurs at a high price like $200/share.

A very successful bullish call for the speaker, who calls it one of his 'favorite biotech picks' and expects the stock to hit 106.

Mentioned alongside Sarepta as a stock the speaker likes, indicating a bullish view.

The speaker is long the stock and identifies it as one of the 'big ones' with an upcoming binary event.

This is Martin Shkreli's specific long pick. He is very bullish due to his expertise in the sector and provides a specific price target of 200.

Mentioned briefly as a biotech stock the speaker likes and considers a 'long' position.

Very bullish view, described as a prime buyout/M&A target with a high likelihood of success. The stock is expected to 'keep steadily marching up' even without a buyout.

Mentioned briefly with a question about a potential earnings call, but with no further context, opinion, or analysis provided.